Do deaths from competing risks influence COPD patterns in China and high socio-demographic index countries?: a cross-sectional analysis of summary statistics from the Global Burden of Disease Study 2017.
chronic obstructive pulmonary disease
competing risks
mortality
risk factors
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
23 03 2022
23 03 2022
Historique:
entrez:
24
3
2022
pubmed:
25
3
2022
medline:
28
4
2022
Statut:
epublish
Résumé
To explore possible reasons for the difference in chronic obstructive pulmonary disease (COPD) incidence/mortality rates between China and high socio-demographic index (SDI) countries. A cross-sectional analysis of summary statistics from the Global Burden of Disease Study 2017. Data were publicly available and de-identified, and individuals were not involved. We extracted the age-standardised and age-specific incidence/mortality rates, and risk factors attributed to COPD in China and high SDI countries from the Global Burden of Disease Study 2017. We first described differences in COPD patterns (ie, incidence and mortality rates) in China and high SDI countries briefly, and then explored possible reasons for driving such differences by comparing rankings for six well-established COPD risk factors and estimating change points in age-specific incidence and mortality rates for COPD and several commonly encountered competing risks using segmented regression models. Differences in age-standardised incidence and mortality rates for COPD between China and high SDI countries converged during 1990-2017 but still differed, particularly for mortality rates. Smoking was the leading attributable risk factor followed by ambient air pollution, with higher rankings for occupational risks in China than in high SDI countries. The change point was ~80 years for age-specific COPD mortality rate in both China and high SDI countries. However, the change point for COPD incidence was 5-year later in China (~65 years) than in high SDI countries (~60 years). The change points for mortality rates due to competing risks (eg, ischaemic heart disease) also varied between settings. Differences in risk factors largely shaped the differences in COPD patterns between China and high SDI countries. Varying patterns of mortality due to competing risks might also contribute to the discrepancy in COPD mortality rates, by affecting the survival of the underlying population.
Identifiants
pubmed: 35321891
pii: bmjopen-2021-050080
doi: 10.1136/bmjopen-2021-050080
pmc: PMC8943480
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e050080Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Eur Respir J. 2009 May;33(5):1165-85
pubmed: 19407051
Value Health Reg Issues. 2017 May;12:112-114
pubmed: 28648308
Eur Respir J. 2008 Jan;31(1):204-12
pubmed: 18166598
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Breathe (Sheff). 2019 Mar;15(1):24-35
pubmed: 30838057
Thorax. 2005 Jul;60(7):570-5
pubmed: 15994265
Chest. 2011 Apr;139(4):920-929
pubmed: 21467059
BMJ. 2020 Feb 19;368:m234
pubmed: 32075787
Thorax. 2011 Sep;66(9):775-81
pubmed: 21653926
Chest. 2008 Feb;133(2):517-27
pubmed: 18252918
Lancet. 2007 Sep 1;370(9589):751-7
pubmed: 17765524
Lancet Respir Med. 2015 Feb;3(2):159-170
pubmed: 25680912
Ann Intern Med. 1980 Sep;93(3):391-8
pubmed: 6776858
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Lancet. 2013 Jun 8;381(9882):1987-2015
pubmed: 23746901
Sci Rep. 2015 Oct 15;5:14884
pubmed: 26469995
Lancet. 2017 May 13;389(10082):1931-1940
pubmed: 28513453
Lancet Respir Med. 2020 Jun;8(6):585-596
pubmed: 32526187
Lancet Respir Med. 2018 Jun;6(6):421-430
pubmed: 29650407
Lancet. 2019 Sep 28;394(10204):1145-1158
pubmed: 31248666
Am J Respir Crit Care Med. 2007 Aug 1;176(3):285-90
pubmed: 17478615
Lancet. 2008 Oct 25;372(9648):1473-83
pubmed: 18835640
Respir Med. 2012 Apr;106(4):515-21
pubmed: 22100536
J Clin Pharm Ther. 2002 Aug;27(4):299-309
pubmed: 12174032
Expert Rev Pharmacoecon Outcomes Res. 2020 Dec;20(6):661-672
pubmed: 31596632
Lancet. 2014 Aug 2;384(9941):427-37
pubmed: 24797573
Am J Respir Crit Care Med. 2010 Sep 1;182(5):693-718
pubmed: 20802169
Lancet Public Health. 2019 Sep;4(9):e449-e461
pubmed: 31493842
BMJ. 2014 Aug 21;349:g5060
pubmed: 25146097
Lancet Respir Med. 2017 Sep;5(9):691-706
pubmed: 28822787
Lancet. 2011 Sep 10;378(9795):991-6
pubmed: 21907862
Stat Med. 2003 Oct 15;22(19):3055-71
pubmed: 12973787
Lancet. 2017 May 13;389(10082):1885-1906
pubmed: 28390697
Ann Intern Med. 1987 Apr;106(4):512-8
pubmed: 3826952
Chest. 2015 Oct;148(4):971-985
pubmed: 25950276
JAMA. 1994 Nov 16;272(19):1497-505
pubmed: 7966841
N Engl J Med. 2009 Jan 8;360(2):150-9
pubmed: 19129528
Lancet. 2018 Nov 10;392(10159):1923-1994
pubmed: 30496105
Am J Respir Crit Care Med. 2018 Jul 1;198(1):51-57
pubmed: 29442524
Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582
pubmed: 28128970
Chest. 2010 Jul;138(1):20-31
pubmed: 20139228
Chest. 2018 Sep;154(3):474-475
pubmed: 30195339